Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 12:38 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2161–2184 of 3,534 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Saline (Placebo Control) Clear all

Conditions: Coronavirus Disease 2019
Interventions: Placebos, Leronlimab (700mg); Drug
Lead sponsor: CytoDyn, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 2
States / cities: Aventura, Florida • Gainesville, Georgia

Conditions: Sepsis
Interventions: Drotrecogin alfa (activated), Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: Up to 17 Years
Enrollment: 474 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 23
States / cities: Birmingham, Alabama • Tucson, Arizona • Tuscon, Arizona + 20 more

Conditions: Memory Losses, Amnesia-Memory Loss
Interventions: Propofol, Thiopental Sodium, Dexmedetomidine Hydrochloride, Midazolam Hydrochloride, placebo; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years to 50 Years
Enrollment: 79 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004 – 2008
U.S. locations: 1
States / cities: New York, New York

Conditions: Acute Respiratory Distress Syndrome (ARDS)
Interventions: Budesonide, Placebo, Formoterol; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 5
States / cities: Tucson, Arizona • Stanford, California • Jacksonville, Florida + 2 more

Conditions: COPD Exacerbation
Interventions: Formoterol, Placebo; Drug · Other
Lead sponsor: University of Tennessee Graduate School of Medicine; Other
Eligibility: 40 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Knoxville, Tennessee

Conditions: Renal Colic
Interventions: Lidocaine, Ketorolac; Drug
Lead sponsor: The Brooklyn Hospital Center; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Brooklyn, New York

Conditions: FSHD - Facioscapulohumeral Muscular Dystrophy
Interventions: ULSC, Placebo; Biological
Lead sponsor: Restem, LLC.; Industry
Eligibility: 15 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Respiratory Distress Syndrome in Premature Infant, Bronchopulmonary Dysplasia
Interventions: recombinant human CC10 (rhCC10), placebo; Drug
Lead sponsor: Clarassance, Inc.; Industry
Eligibility: 24 Weeks to 29 Weeks
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2003
U.S. locations: 4
States / cities: Wilmington, Delaware • Baltimore, Maryland • Mineola, New York

Conditions: Herpes Simplex
Interventions: Lower dose formulation of HSV vaccine (GSK4108771A), Low dose formulation of HSV vaccine (GSK4108771A), Medium dose formulation of HSV vaccine (GSK4108771A), High dose formulation of HSV vaccine (GSK4108771A), Placebo (saline); Biological · Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 40 Years
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 2
States / cities: Lenexa, Kansas • Rochester, New York

Conditions: Healthy
Interventions: EXPAREL, Bupivacaine Hydrochloride, Placebo; Drug · Other
Lead sponsor: Pacira Pharmaceuticals, Inc; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Pancreatic Cancer
Interventions: Alcohol Block; Procedure
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University; Other
Eligibility: 18 Years and older
Enrollment: 438 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Type1 Diabetes Mellitus
Interventions: Glucagon-like peptide-1, Placebos; Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 50 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Vasoplegic Syndrome
Interventions: Hydroxocobalamin, Cardiopulmonary Bypass, Placebos; Drug · Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Influenza
Interventions: Investigational H9N2 vaccine GSK2654911A, Investigational H9N2 vaccine GSK2654909A, Placebo; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 422 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 3
States / cities: Miami, Florida • Edison, New Jersey • Austin, Texas

Conditions: Peripheral Vascular Diseases
Interventions: G-CSF, Placebo, Aspirin, Clopidogrel; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Unresectable or Metastatic Hepatocellular Carcinoma, Child-Pugh A Hepatocellular Carcinoma, Failure of First-Line Treatment That Included an Approved Anti PD-(L)1 Compound
Interventions: Visugromab RDE (recommended dose for expansion), Nivolumab, Lenvatinib, Placebo Saline Infusion; Biological · Drug · Other
Lead sponsor: CatalYm GmbH; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 6
States / cities: Irvine, California • Los Angeles, California • Orange, California + 3 more

Conditions: Radiocontrast Nephropathy
Interventions: N-Acetylcysteine (NAC), 0.9% Sodium-chloride; Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years to 120 Years
Enrollment: 399 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Brain Injuries, Traumatic
Interventions: Sodium Lactate, Placebo; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: SARS-CoV-2, Influenza
Interventions: mRNA-1083, Placebo, Influenza Vaccine, COVID-19 Vaccine; Biological
Lead sponsor: ModernaTX, Inc.; Industry
Eligibility: 50 Years and older
Enrollment: 8,061 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 146
States / cities: Anniston, Alabama • Birmingham, Alabama • Cullman, Alabama + 122 more

Conditions: Crohn's Disease
Interventions: Vedolizumab, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 3
States / cities: Nashville, Tennessee • Southlake, Texas • Seattle, Washington

Conditions: Ketosis
Interventions: Ketone Supplement, Beverage Tolerability Questionnaire (BTQ) and satiety visual analogue scale, Blood Draw, Breath Reading, Heart Rate Variability, CGM/CKM, DXA, Urine Analysis; Dietary Supplement · Behavioral · Biological + 2 more
Lead sponsor: Ohio State University; Other
Eligibility: 20 Years to 30 Years · Male only
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Healthy
Interventions: Clinical Center Reference Endotoxin (CCRE), Normal saline; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 50 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: COVID-19
Interventions: Placebo, Remdesivir; Other · Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 1,062 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 41
States / cities: Birmingham, Alabama • La Jolla, California • Los Angeles, California + 35 more

Conditions: Major Depressive Disorder With Suicidal Ideation With Intent
Interventions: MIJ821 Intravenous Injection, Placebo Intravenous Injection; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 199 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 6
States / cities: Birmingham, Alabama • Farmington, Connecticut • Oakland Park, Florida + 3 more

Search by objective public record fields.

Double Blind, Placebo Controlled Study of Safety and Efficacy of Leronlimab in Patients With "Long" COVID-19

Investigation of the Efficacy and Safety of Drotrecogin Alfa (Activated) in Pediatric Severe Sepsis

Effect of Affective Content on Drug Induced Amnesia of Episodic Memory

LIPS-B: Lung Injury Prevention Study With Budesonide and Beta

COPD Aerosol Study Comparing the Efficacy of Nebulizers Versus Dry Powder Inhalers

Lidocaine vs Ketorolac for Management of Renal Colic in the Emergency Department

Safety and Preliminary Efficacy of ULSC in Facioscapulohumeral Muscular Dystrophy (FSHD)

Safety, Pk and Anti-inflammatory Effects of CC10 Protein in Premature Infants With Respiratory Distress Syndrome (RDS)

A Study on the Reactogenicity, Safety and Immune Response of a Vaccine Against Herpes Simplex Virus (HSV)-2 in Healthy Participants Aged 18-40 Years

Evaluation of Safety, Pharmacokinetics and Pharmacodynamics of EXPAREL® Administered Via a Single Intrathecal Injection to Healthy Volunteers

Intraoperative Celiac Plexus Neurolysis for Patients With Operable Pancreatic and Periampullary Cancer

Glucagon-like Peptide-1 in Type 1 Diabetes

Vitamin B12a Vasoplegic Syndrome

Study to Evaluate the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccines GSK2654911A and GSK2654909A Administered to Adults 18 to 64 Years of Age

Stem Cell Mobilization by G-CSF to Treat Severe Peripheral Artery Disease

Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 Failure

N-Acetylcysteine to Prevent Radiocontrast Nephropathy in Emergency Department Patients

Exogenous Sodium Lactate Infusion in Traumatic Brain Injury (ELI-TBI)

A Study of mRNA-1083 (SARS-CoV-2 and Influenza) Vaccine in Healthy Adult Participants, ≥50 Years of Age

Vedolizumab IV 300 mg in the Treatment of Fistulizing Crohn's Disease

Strategies to Augment Ketosis: Optimization of Ketone Delivery Strategies

Effects of 20,000 EU of Clinical Center Reference Endotoxin (CCRE) Versus Placebo(ENDOHEART)

Adaptive COVID-19 Treatment Trial (ACTT)

Study of Efficacy and Safety of MIJ821 in Addition to Comprehensive Standard of Care on the Rapid Reduction of Symptoms of Major Depressive Disorder in Subjects Who Have Suicidal Ideation With Intent